Outcome of Synthetic Bone Graft GENEX in the treatment of bony defects
Research type
Research Study
Full title
Radiographic analysis and clinical outcomes of an absorbable calcium composite synthetic bone graft (GENEX) in the treatment of bony defects
IRAS ID
288191
Contact name
Bogdan Andronic Andronic
Contact email
Sponsor organisation
Hull Teaching University Hospitals
Duration of Study in the UK
0 years, 4 months, 15 days
Research summary
GeneX (Biocomposites Ltd., Keele, UK) is a commercially available synthetic graft which contains beta-tri-calcium phosphate and calcium sulfate. It is a biphasic absorbable, osteoconductive (scaffold) putty, which can be injected in bone defects, thereby providing support, preventing collapse, and stimulating bone regrowth.
We propose this study to evaluate the outcomes of the effectiveness of a single synthetic calcium composite graft (GeneX) in treatment of bone defects for trauma/elective cases treated in a single Level 1 Major Trauma Centre (MTC).
All patients who have undergone GeneX application from 2012 to 2019 would be included in the study. We expect to complete the study in 6 - 12 months post approval.REC name
North West - Greater Manchester West Research Ethics Committee
REC reference
21/NW/0230
Date of REC Opinion
12 Oct 2021
REC opinion
Further Information Favourable Opinion